Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.

ABSTRACT:

Unlabelled

New treatments for hepatitis C virus (HCV) may be highly effective but are associated with substantial costs that may compel clinicians and patients to consider delaying treatment. This study investigated the cost-effectiveness of these treatments with a focus on patients in early stages of liver disease. We developed a state-transition (or Markov) model to calculate costs incurred and quality-adjusted life-years (QALYs) gained following HCV treatment, and we computed incremental cost-effectiveness ratios (cost per QALY gained, in 2012 US dollars) for treatment at different stages of liver disease versus delaying treatment until the subsequent liver disease stage. Our analysis did not include the potential treatment benefits associated with reduced non-liver-related mort

SUBMITTER: Leidner AJ 

PROVIDER: S-EPMC5802336 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature